Company Overview
About Aignostics
Aignostics is a Berlin-based precision pathology company founded in 2019 as a spinout from Charité – Universitätsmedizin Berlin, one of Europe''s largest university hospitals. The company develops foundation models and AI-powered image analysis tools for computational pathology — applying deep learning to digitized histopathology slides (whole slide images) to detect, classify, and quantify cellular and tissue features at scale. Its technology enables pharmaceutical companies, contract research organizations (CROs), and diagnostic laboratories to analyze tissue samples faster, more consistently, and with greater quantitative depth than human pathologists alone.
Business Model & Competitive Advantage
Aignostics raised over €45M in total funding, including a €37M Series B in 2024 led by Balderton Capital with participation from Redalpine, Heartcore, Wilbe, and others. Strategic partnerships include AstraZeneca, Bayer, and Charité Berlin, positioning Aignostics at the interface of clinical research, drug development, and diagnostic innovation. The company''s AI models are trained on large-scale, curated pathology datasets and are designed to support both exploratory biomarker discovery in early-phase drug trials and regulatory-grade analysis in clinical diagnostics.
Competitive Landscape 2025–2026
Aignostics'' foundation model approach — building large, general-purpose pathology AI models that can be fine-tuned for specific indications — differentiates it from earlier, narrowly trained diagnostic AI tools. This positions the company alongside global leaders in computational pathology such as Paige.AI and PathAI, with a distinct European clinical data advantage through its Charité partnership. As digital pathology adoption accelerates driven by whole slide imaging infrastructure investment, Aignostics is positioned to serve as a core AI intelligence layer for both pharmaceutical R&D and next-generation clinical diagnostic workflows.
Key Differentiators
Emerging Innovator
Aignostics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Similar Brands
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Aignostics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Aignostics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Aignostics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Aignostics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →